
|Articles|March 23, 2009
REMS: Is it the end of the world as we know it? Part2
Advertisement
REMS: Is it the end of the world as we know it?
Risk Evaluation and Mitigation Strategies: For manufacturers, do REMS represent a tremendous potential for confusion or an opportunity for growth? Perhaps both. Manufacturers who implement effective programs can enhance patient access to medications, further ensure appropriate utilization and potentially improve patient outcomes. Manufacturers whose execution falls short stand to lose market share or even risk increased regulatory scrutiny.
Add this Podcast feed to your media player
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Makes Leadership Overhaul Following Commissioner Makary’s Departure: Report
2
Regeneron Enters $2.3 Billion Collaboration with Parabilis Medicines to Discover & Develop Multiple Therapeutic Candidates
3
How Pharma is Adjusting Strategies for Changing Dynamics at FDA
4
FDA Approves Baxdrostat for Uncontrolled Hypertension in First-in-Class Entry
5




